Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and ...
Longeveron said the Food and Drug Administration no longer refers to its Phase 2b clinical trial for a potential treatment for hypoplastic left heart syndrome (HLHS) as pivotal.
Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced ...
POCATELLO — With all the medical needs her two-month-old daughter Auzzy has, Lauren Price says she sometimes feels more like a nurse and, at times, has to remind herself to step back and just be a ...
Stocktwits on MSN
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design
The agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.” ・As a result, the FDA no longer considers the study to be “pivotal.” ...
Every case of HLHS is unique because there are many different things that can go wrong during the early development of the heart. If we're able to uncover what drives this disease biologically, it may ...
Children's Hospital Colorado (Children's Colorado) successfully performed the hospital's first-ever heart and liver dual organ transplant, with support from dozens of team members across 25 different ...
Hypoplastic Left Heart Syndrome is a rare, uniformly fatal condition without immediate treatment.
CORPUS CHRISTI, Texas (KTRK) -- A Corpus Christi family is going through a big battle. Soon, the mother will be traveling to Houston to give birth to her son who, right now, only has half his heart.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results